Update in Hepatology
Authors: Eugene R. Schiff
Journal: Annals of Internal Medicine (2000)

Updates from the Annual Session21 March 2000Update in HepatologyEugene R. Schiff, MDEugene R. Schiff, MDFrom Center for Liver Diseases, Miami, Florida.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-6-200003210-00006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Among the wide range of reports on hepatologic issues published in 1998, I address key research in the areas of viral hepatitis, drug-induced hepatotoxicity, and noninvasive diagnostic assessment using magnetic resonance cholangiography.Viral HepatitisFor practical purposes, the dominant forms of hepatitis in the United States are A, B, and C. The D (“delta”) hepatitis virus is becoming less prevalent throughout the world. Hepatitis E remains a major problem in developing countries worldwide but is rare in this country. Other viruses—hepatitis G among them—have been described but are not clinically important. There is some question of whether they should even ...References1. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183-7. CrossrefMedlineGoogle Scholar2. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8. CrossrefMedlineGoogle Scholar3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al . Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet. 1998;352:1426-32. CrossrefMedlineGoogle Scholar4. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al . Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38-41. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Center for Liver Diseases, Miami, Florida.Disclaimer: The author has served as principal investigator, co-investigator, scientific advisor, or speaker for numerous pharmaceutical firms, many of which are competitors in the marketplace.Corresponding Author: Eugene R. Schiff, MD, Division of Hepatology, Center for Liver Diseases, Suite 1101, Miami, FL 33136; e - mail, [email protected] PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUpdate in Hepatology Buddha Basnyat and R.M. Scott Metrics Cited byDiscovery of bakuchiol as an AIM2 inflammasome activator and cause of hepatotoxicityAcute Viral HepatitisSpontaneous renal laceration as the presenting feature of polyarteritis nodosa in a patient with familial Mediterranean fever after hepatitis A infectionPossible hepatotoxicity of chronic marijuana usageDrug-induced cholestasisUpdate in HepatologyBuddha Basnyat and R.M. Scott 21 March 2000Volume 132, Issue 6Page: 460-466KeywordsAcute liver failureChronic hepatitis BChronic hepatitis CDrugsHepatitis AHepatitis CInterferonsLiverRNAVaccines ePublished: 15 August 2000 Issue Published: 21 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...